3,4,5-trimethoxyamphetamine
3,4,5-Trimethoxyamphetamine (TMA) is a psychoactive drug and hallucinogen that belongs to the amphetamine class of compounds. It is known for its psychedelic effects similar to those of LSD and mescaline. TMA is one of the several compounds in the series of substituted amphetamines, which include more widely known substances such as MDMA (Ecstasy) and methamphetamine.
Chemistry[edit | edit source]
3,4,5-Trimethoxyamphetamine is chemically related to mescaline, sharing the same methoxy groups at the 3, 4, and 5 positions of the benzene ring. The presence of these methoxy groups significantly influences the compound's pharmacological properties, making it a potent serotonin receptor agonist. The chemical formula for TMA is C12H19NO3.
Pharmacology[edit | edit source]
The pharmacological action of TMA is primarily through its agonist activity at the serotonin receptor, particularly at the 5-HT2A receptor, which is known to be responsible for its psychedelic effects. Like other psychedelics, TMA induces intense visual and auditory hallucinations, altered states of consciousness, and profound changes in thought, mood, and perception.
Effects[edit | edit source]
The effects of 3,4,5-Trimethoxyamphetamine can vary greatly depending on the dose, individual physiology, and environmental factors. Commonly reported effects include visual hallucinations, enhanced colors, emotional uplift, euphoria, and increased introspection. However, negative effects such as anxiety, paranoia, and disorientation can also occur, especially at higher doses.
History[edit | edit source]
TMA was first synthesized and investigated in the early 1960s by Alexander Shulgin, a renowned chemist and pharmacologist known for his extensive work on psychoactive compounds. Shulgin's research on TMA and other related compounds was documented in his books PiHKAL (Phenethylamines I Have Known And Loved), which has become a seminal text in the study of psychoactive substances.
Legal Status[edit | edit source]
The legal status of 3,4,5-Trimethoxyamphetamine varies by country, but it is often classified as a controlled substance due to its psychoactive properties and potential for abuse. In many jurisdictions, the possession, manufacture, and distribution of TMA are regulated under drug control laws.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD